NGM Biopharmaceuticals, Inc. (NGM) Social Stream
NGM BIOPHARMACEUTICALS INC (NGM) Price Targets From Analysts
Use the tables below to see what analysts covering NGM BIOPHARMACEUTICALS INC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-08 | 5 | $42 | $30 | $34.8 | $1.19 | 2824.37% |
| 2022-05-12 | 5 | $42 | $32 | $35.2 | $1.19 | 2857.98% |
| 2022-05-31 | 6 | $42 | $29 | $34.166 | $1.19 | 2771.09% |
| 2022-09-15 | 7 | $42 | $25 | $32.857 | $1.19 | 2661.09% |
| 2022-10-03 | 6 | $42 | $25 | $32.5 | $1.19 | 2631.09% |
| 2022-10-07 | 6 | $42 | $25 | $31.5 | $1.19 | 2547.06% |
| 2022-11-03 | 6 | $9 | $4 | $5.5 | $1.19 | 362.18% |
| 2023-03-03 | 6 | $9 | $4 | $5.833 | $1.19 | 390.17% |
| 2023-03-30 | 6 | $9 | $4 | $5.666 | $1.19 | 376.13% |
| 2023-05-05 | 7 | $9 | $4 | $5.666 | $1.19 | 376.13% |
| 2023-05-15 | 7 | $9 | $4 | $5.714 | $1.19 | 380.17% |
| 2023-08-04 | 6 | $9 | $4 | $6 | $1.19 | 404.2% |
| 2023-11-02 | 6 | $9 | $2 | $5.666 | $1.19 | 376.13% |
| 2023-11-07 | 6 | $7 | $2 | $4.833 | $1.19 | 306.13% |
| 2023-11-22 | 6 | $6 | $2 | $4.25 | $1.19 | 257.14% |
The Trend in the Analyst Price Target
Over the past 42 months, NGM's average price target has gone down $25.46.
Over the past 45 weeks, NGM's average upside potential has been 170.85%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-01-10 | 6 | 9 | 4 | 5.833 | 4.84 | 20.52% |
| 2023-05-05 | 7 | 9 | 4 | 5.714 | 4.08 | 40.05% |
| 2023-05-05 | 7 | 9 | 4 | 5.666 | 4.08 | 38.87% |
| 2023-05-15 | 6 | 9 | 4 | 6.000 | 3.33 | 80.18% |
| 2023-08-04 | 6 | 9 | 4 | 6.000 | 2.24 | 167.86% |
NGM Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.83 | 3 | 1 | 2 | 0 | 0 | 6 |
The Trend in the Broker Recommendations
Over the past 52 weeks, NGM's average broker recommendation rating improved by 0.34.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- NGM has a greater upside potential (average analyst target price relative to current price) than 1621.82% of all US stocks.
- In terms of how NGM BIOPHARMACEUTICALS INC fares relative to all US stocks, note that its average analyst price target is higher than 360.2% of that group.
- In terms of how NGM BIOPHARMACEUTICALS INC fares relative to stocks in the mid market cap category, note that its variance in analysts' estimates is lower than -1032.06% of that group.
- To contextualize these metrics, consider that out of stocks in the mid market cap category, NGM BIOPHARMACEUTICALS INC's number of analysts covering the stock is greater than 537.91% of them.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to NGM BIOPHARMACEUTICALS INC are ALLK, RCKT, and CERE.
View All Top Stocks by Price Target
Is NGM a Buy, Hold or Sell? See the POWR Ratings now!